New Guidelines Endorse Self-Swab Kits for Cervical Cancer Screening
The American Cancer Society has updated its guidelines to endorse the use of self-swab kits to screen for human papillomavirus (HPV), citing a significant reduction in barriers to cervical cancer screening. The new recommendations follow the FDA's approval of the first at-home HPV test, known as the Teal Wand.
According to the guidelines, women with an average risk of developing cervical cancer can now use self-swab kits to collect and send their own vaginal specimens for testing. This approach is expected to improve compliance rates and reduce the risk of cervical cancer, which has seen a significant decline in recent decades but plateaued over the past decade.
The guidelines note that 94% of women prefer home-collection screening methods, as long as they are as reliable as traditional clinic-based tests. The Teal Wand, the FDA-approved at-home test, is said to be just as accurate as in-office tests for detecting HPV.
By allowing individuals to collect their own specimens and send them to a lab for testing, self-swab kits aim to overcome common barriers to screening, such as lack of information, access to healthcare, and embarrassment about pelvic exams. The guidelines also outline specific recommendations for when screening can be stopped based on negative test results.
With cervical cancer incidence rates expected to remain stable in the coming years, the new guidelines offer a promising solution to improving adherence to recommended screenings. By making testing more accessible and convenient, these updated guidelines aim to help reduce the risk of developing and dying from this preventable disease.
The American Cancer Society has updated its guidelines to endorse the use of self-swab kits to screen for human papillomavirus (HPV), citing a significant reduction in barriers to cervical cancer screening. The new recommendations follow the FDA's approval of the first at-home HPV test, known as the Teal Wand.
According to the guidelines, women with an average risk of developing cervical cancer can now use self-swab kits to collect and send their own vaginal specimens for testing. This approach is expected to improve compliance rates and reduce the risk of cervical cancer, which has seen a significant decline in recent decades but plateaued over the past decade.
The guidelines note that 94% of women prefer home-collection screening methods, as long as they are as reliable as traditional clinic-based tests. The Teal Wand, the FDA-approved at-home test, is said to be just as accurate as in-office tests for detecting HPV.
By allowing individuals to collect their own specimens and send them to a lab for testing, self-swab kits aim to overcome common barriers to screening, such as lack of information, access to healthcare, and embarrassment about pelvic exams. The guidelines also outline specific recommendations for when screening can be stopped based on negative test results.
With cervical cancer incidence rates expected to remain stable in the coming years, the new guidelines offer a promising solution to improving adherence to recommended screenings. By making testing more accessible and convenient, these updated guidelines aim to help reduce the risk of developing and dying from this preventable disease.